Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases

Myocyte enhancer factor 2C (MEF2C) is increasingly expressed in mice along with breast cancer brain metastases (BCBM) development. We aim to ascertain MEF2C expression in human BCBM, establish the relationship with disease severity, disclose the involvement of vascular endothelial growth factor receptor-2 (VEGFR-2) and β-catenin, also known as KDR and CTNNB1, respectively, and investigate if matched primary tumors express the protein. We studied resected BCBM for the expression of MEF2C, VEGFR-2, and ß-catenin, as well as proliferation (Ki-67) and epithelial (pan Cytokeratin) markers, and related experimental and clinical data. MEF2C expression was further assessed in matched primary tumors and non-BCBM samples used as controls. MEF2C expression was observed in BCBM, but not in controls, and was categorized into three phenotypes (P): P1, with extranuclear location; P2, with extranuclear and nuclear staining, and P3, with nuclear location. Nuclear translocation increased with metastases extension and Ki-67-positive cells number. P1 was associated with higher VEFGR-2 plasma membrane immunoreactivity, whereas P2 and P3 were accompanied by protein dislocation. P1 was accompanied by β-catenin membrane expression, while P2 and P3 exhibited β-catenin nuclear translocation. Primary BC samples expressed MEF2C in mammary ducts and scattered cells in the parenchyma. MEF2C emerges as a player in BCBM associated with disease severity and VEGFR-2 and β-catenin signaling.

[1]  S. Booth,et al.  Downregulation of circulating miR 802‐5p and miR 194‐5p and upregulation of brain MEF2C along breast cancer brain metastasization , 2020, Molecular oncology.

[2]  J. Pimentel,et al.  Thioredoxin, glutathione and related molecules in tumors of the nervous system. , 2019, Current medicinal chemistry.

[3]  C. Brancolini,et al.  MEF2 and the tumorigenic process, hic sunt leones. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[4]  Chae-Yong Kim,et al.  Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort , 2018, The breast journal.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  Yin Lu,et al.  Emerging findings into molecular mechanism of brain metastasis , 2018, Cancer medicine.

[7]  F. Cardoso,et al.  Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). , 2018, Breast.

[8]  Arash Salmaninejad,et al.  Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis , 2018, Cellular Oncology.

[9]  Jia Liu,et al.  MEF2 signaling and human diseases , 2017, Oncotarget.

[10]  M. Brito,et al.  Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall , 2017, Angiogenesis.

[11]  M. Videira,et al.  Brain metastasization of breast cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[12]  D. Yin,et al.  Myocyte enhancer factor 2C and its directly-interacting proteins: A review. , 2017, Progress in biophysics and molecular biology.

[13]  S. Bates,et al.  Current challenges in the management of breast cancer brain metastases. , 2017, Seminars in oncology.

[14]  S. P. Herbert,et al.  MEF2 transcription factors are key regulators of sprouting angiogenesis , 2016, Genes & development.

[15]  Emma Gordon,et al.  Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.

[16]  Dimitris Basagiannis,et al.  Constitutive Endocytosis of VEGFR2 Protects the Receptor against Shedding* , 2016, The Journal of Biological Chemistry.

[17]  N. Han,et al.  Time course analysis based on gene expression profile and identification of target molecules for colorectal cancer , 2016, Cancer Cell International.

[18]  I. Wilhelm,et al.  Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K , 2016, Cell adhesion & migration.

[19]  A. Vincent-Salomon,et al.  Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay , 2016, PloS one.

[20]  M. Marra,et al.  MEF2 transcription factors: developmental regulators and emerging cancer genes , 2015, Oncotarget.

[21]  C. Brancolini,et al.  The MEF2–HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro , 2015, Journal of Cell Science.

[22]  F. Winkler The brain metastatic niche , 2015, Journal of Molecular Medicine.

[23]  M. Videira,et al.  Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. , 2014, Biochimica et biophysica acta.

[24]  Qi Zhang,et al.  Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling , 2014, Oncogene.

[25]  Weiyu Chen,et al.  MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry , 2014, Tumor Biology.

[26]  Y. Miao,et al.  Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism , 2014, Molecular Cancer.

[27]  A. Redig,et al.  Breast cancer as a systemic disease: a view of metastasis , 2013, Journal of internal medicine.

[28]  O. Chinot,et al.  Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.

[29]  A. Wells,et al.  Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer , 2012, Cancer and Metastasis Reviews.

[30]  F. Su,et al.  Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.

[31]  C. Perou,et al.  The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases , 2011, Cancer.

[32]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[33]  E. Duh,et al.  Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. , 2008, Investigative ophthalmology & visual science.

[34]  J. Ostrander,et al.  Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. , 2007, Cancer research.

[35]  Kay Nieselt,et al.  Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.

[36]  N. Copeland,et al.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.

[37]  S. Eccles,et al.  Breast cancer metastasis: when, where, how? , 2005, The Lancet.